Investor Presentation First Nine Months of 2023
26
Investor presentation
First nine months of 2023
Partnerships and acquisitions support future research and
development
Selected licenses
Acquisitions
2019
EpiDestiny
Novel treatment for
CVD/Rare disease
TA: Therapy area; CVD: Cardiovascular Disease; siRNA: Small interfering RNA
Note: Deal flow from 2019-2023Q3;
2020
2021
2022
2023
Emisphere
Oral formulations of
therapeutics
CORVIDIA
Novel treatments for
CVD/Rare disease
of prothena
Novel treatment for
CVD/Rare disease
Dicerna™
siRNA treatments
forma
THERAPEUTICS.
Novel treatments for
CVD/Rare disease
inversago
PHARMA
Novel treatments for
metabolic diseases
Heartseed
Novel treatment for
CVD/Rare disease
Ventus
THERAPEUTICS
Novel treatment for
metabolic diseases
Valo
Novel treatment for
CVD/Rare disease
Novo NordiskⓇView entire presentation